Efficacy of 99mTc-DTPA SPECT/CT in diagnosing Orbitopathy in graves’ disease

BMC Endocrine Disorders

Table 5 Assessment parameters for diagnostic methods CAS, MRI and SPECT/CT in detecting active GO

	CAS	MRI	SPECT/CT	p
Sensitivity	0.86	0.93	0.93	0.048^{a, b/c}
−95% CI	0.51	0.81	0.83
+ 95% CI	0.92	0.98	0.99
Specificity	0.56	0.78	0.89	0.039^a,b,c
−95% CI	0.29	0.55	0.58
+ 95% CI	0.56	0.89	0.99
PPV	0.75	0.87	0.93	0.031^a,b,c
−95% CI	0.47	0.61	0.73
+ 95% CI	0.81	0.97	0.98
NPV	0.71	0.88	0.89	0.049^a,b,c
−95% CI	0.54	0.66	0.77
+ 95% CI	0.76	0.95	0.98
ACC	0.74	0.87	0.91	0.050^a,b,c
−95% CI	0.63	0.58	0.92
+ 95% CI	0.88	0.94	0.98

PPV positive predictive value, NPV, negative positive predictive value, ACC accuracy, other abbreviations, see Table 1
^{a, b, c} - statistically significant difference between parameters of three examinations (CAS, MRI, and SPECT/CT)
^{a, b/c} - statistically significant difference between parameters of CAS and (MRI or SPECT/CT), lack of statistically significant difference between MRI and SPECT/CT

ISSN: 1472-6823